These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 21995398)

  • 1. Vemurafenib in melanoma with BRAF V600E mutation.
    Morita H; Nagai R
    N Engl J Med; 2011 Oct; 365(15):1448; author reply 1450. PubMed ID: 21995398
    [No Abstract]   [Full Text] [Related]  

  • 2. Vemurafenib in melanoma with BRAF V600E mutation.
    Dalle S; Poulalhon N; Thomas L
    N Engl J Med; 2011 Oct; 365(15):1448-9; author reply 1450. PubMed ID: 21995399
    [No Abstract]   [Full Text] [Related]  

  • 3. Vemurafenib in melanoma with BRAF V600E mutation.
    Lott JP
    N Engl J Med; 2011 Oct; 365(15):1449-50; author reply 1450. PubMed ID: 21995400
    [No Abstract]   [Full Text] [Related]  

  • 4. Improved survival with vemurafenib in melanoma with BRAF V600E mutation.
    Chapman PB; Hauschild A; Robert C; Haanen JB; Ascierto P; Larkin J; Dummer R; Garbe C; Testori A; Maio M; Hogg D; Lorigan P; Lebbe C; Jouary T; Schadendorf D; Ribas A; O'Day SJ; Sosman JA; Kirkwood JM; Eggermont AM; Dreno B; Nolop K; Li J; Nelson B; Hou J; Lee RJ; Flaherty KT; McArthur GA;
    N Engl J Med; 2011 Jun; 364(26):2507-16. PubMed ID: 21639808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vemurafenib: a guide to its use in unresectable or metastatic melanoma.
    Keating GM; Lyseng-Williamson KA
    Am J Clin Dermatol; 2013 Feb; 14(1):65-9. PubMed ID: 23329082
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vemurafenib (RG67204, PLX4032): a potent, selective BRAF kinase inhibitor.
    Patrawala S; Puzanov I
    Future Oncol; 2012 May; 8(5):509-23. PubMed ID: 22646766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma.
    Ravnan MC; Matalka MS
    Clin Ther; 2012 Jul; 34(7):1474-86. PubMed ID: 22742884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Community experience of vemurafenib for BRAF(V600) melanoma.
    Hersey P
    Lancet Oncol; 2014 Apr; 15(4):369-70. PubMed ID: 24582506
    [No Abstract]   [Full Text] [Related]  

  • 9. BRIM-1, -2 and -3 trials: improved survival with vemurafenib in metastatic melanoma patients with a BRAF(V600E) mutation.
    Young K; Minchom A; Larkin J
    Future Oncol; 2012 May; 8(5):499-507. PubMed ID: 22646765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vemurafenib.
    Garbe C; Abusaif S; Eigentler TK
    Recent Results Cancer Res; 2014; 201():215-25. PubMed ID: 24756795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study.
    Chapman PB; Robert C; Larkin J; Haanen JB; Ribas A; Hogg D; Hamid O; Ascierto PA; Testori A; Lorigan PC; Dummer R; Sosman JA; Flaherty KT; Chang I; Coleman S; Caro I; Hauschild A; McArthur GA
    Ann Oncol; 2017 Oct; 28(10):2581-2587. PubMed ID: 28961848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cutaneous manifestations of vemurafenib therapy for metastatic melanoma.
    Owen JL; Lopez IE; Desai SR
    J Drugs Dermatol; 2015 May; 14(5):509-10. PubMed ID: 25942671
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted inhibition of the BRAF pathway in a patient with stage IV melanoma.
    Buckley B; Pierce B
    JAAPA; 2018 May; 31(5):24-26. PubMed ID: 29698368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FDA approves vemurafenib for treatment of metastatic melanoma.
    Oncology (Williston Park); 2011 Sep; 25(10):906. PubMed ID: 22010387
    [No Abstract]   [Full Text] [Related]  

  • 15. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.
    Larkin J; Del Vecchio M; Ascierto PA; Krajsova I; Schachter J; Neyns B; Espinosa E; Garbe C; Sileni VC; Gogas H; Miller WH; Mandalà M; Hospers GA; Arance A; Queirolo P; Hauschild A; Brown MP; Mitchell L; Veronese L; Blank CU
    Lancet Oncol; 2014 Apr; 15(4):436-44. PubMed ID: 24582505
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation.
    Su F; Bradley WD; Wang Q; Yang H; Xu L; Higgins B; Kolinsky K; Packman K; Kim MJ; Trunzer K; Lee RJ; Schostack K; Carter J; Albert T; Germer S; Rosinski J; Martin M; Simcox ME; Lestini B; Heimbrook D; Bollag G
    Cancer Res; 2012 Feb; 72(4):969-78. PubMed ID: 22205714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vemurafenib.
    Flaherty KT; Yasothan U; Kirkpatrick P
    Nat Rev Drug Discov; 2011 Oct; 10(11):811-2. PubMed ID: 22037033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vemurafenib and BRAF inhibition: a new class of treatment for metastatic melanoma.
    Luke JJ; Hodi FS
    Clin Cancer Res; 2012 Jan; 18(1):9-14. PubMed ID: 22083257
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Upcoming strategies for the treatment of metastatic melanoma.
    Spagnolo F; Queirolo P
    Arch Dermatol Res; 2012 Apr; 304(3):177-84. PubMed ID: 22350184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A case report of a patient with metastatic ocular melanoma who experienced a response to treatment with the BRAF inhibitor vemurafenib.
    Maleka A; Åström G; Byström P; Ullenhag GJ
    BMC Cancer; 2016 Aug; 16():634. PubMed ID: 27520988
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.